Table I.

Baseline demographic and osteoarthritic characteristics of the study population.

	Intent-to-Treat Population		Per-Protocol Population
	Placebo (n = 50)	SRHP (n = 50)	Placebo (n = 48)	SRHP (n = 48)
Age, y∗	65.3 (9.9)	65.1 (12.2)	65.8 (14.7)	65.5 (14.2)
Sex, no. (%)
Women	31 (62.0)	34 (68.0)	29 (60.4)	33 (68.8)
Men	19 (38.0)	16 (32.0)	19 (39.6)	15 (31.3)
No. (%) of patients with OA of the hip	19 (38.0)	25 (50.0)	17 (35.4)	24 (50.0)
No. (%) of patients with OA of the knee	31 (62.0)	25 (50.0)	31 (64.6)	24 (50.0)
Hip joint movement, deg∗
Passive flexion	111.05 (12.76)	116.00 (13.92)	111.47 (13.20)	115.62 (14.09)
Active flexion	97.63 (15.49)	105.60 (13.10)†	97.94 (16.01)	105.42 (13.34)‡
Passive external rotation	19.72 (11.56)	26.40 (9.74)	20.00 (16.01)	25.62 (9.13)
Active external rotation	13.06 (10.17)	20.00 (9.79)§	13.44 (10.76)	19.17 (9.05)
Passive internal rotation	28.61 (11.61)	28.80 (13.17)	29.37 (12.09)	28.75 (13.45)
Active internal rotation	21.39 (10.68)	21.20 (12.61)	22.19 (11.10)	21.04 (12.85)
Knee joint movement, deg∗
Passive flexion	128.71 (14.37)	132.40 (9.14)	128.71 (14.37)	132.08 (9.20)
Active flexion	123.55 (14.73)	124.80 (11.77)	120.35 (24.95)	124.58 (11.97)
No. (%) of patients taking concomitant medication
None	15 (30.0)	11 (22.0)	14 (29.2)	10 (20.8)
NSAIDs	20 (40.0)	24 (48.0)	19 (39.6)	23 (47.9)
Paracetamol	12 (24.0)	14 (28.0)	12 (25.0)	14 (29.2)
Opioids	2 (4.0)	0 (0.0)	2 (4.2)	0 (0.0)
Asthma medication	2 (4.0)	0 (0.0)	2 (4.2)	0 (0.0)
Antihypertensive	2 (4.0)	2 (4.0)	2 (4.2)	2 (4.2)
Heart disease medication	5 (10.0)	3 (6.0)	5 (10.4)	3 (6.3)

SRHP = standardized rose-hip powder; OA = osteoarthritis; NSAIDs = nonsteroidal anti-inflammatory drugs.

^∗Values are expressed as mean (SD).

^†P=0.020 versus placebo.

^‡P=0.039 versus placebo.

^§P=0.041 versus placebo.